循环生物活性肾上腺髓质素(bio-ADM)预测脓毒症的血流动力学支持需求与死亡率
该研究为多中心ALBIOS试验的二次分析,纳入956例脓毒症或脓毒性休克患者,随机接受白蛋白或晶体液复苏。第1天血浆bio-ADM中位数110 pg/mL,在脓毒性休克患者中更高,与90天死亡率、多器官衰竭、血流动力学支持治疗平均强度及第一周乳酸变化轨迹相关。在入组时无休克患者中,bio-ADM预测新发心血管功能障碍(OR 1.9,95%CI 1.4-2.5,P<.0001,bio-ADM浓度每增加1个四分位距)。第一周bio-ADM轨迹经临床相关协变量校正后预测90天死亡率(HR 1.3,95%CI 1.2-1.4,P<.0001),第7天降至110 pg/mL以下与90天死亡率明显降低相关。bio-ADM前7天变化不依赖于白蛋白治疗。作者认为bio-ADM可能有助于个体化血流动力学支持治疗,同时避免有害效应,并可能是未来靶向治疗的候选。
要点
- 956例脓毒症或脓毒性休克患者中,第1天血浆bio-ADM中位数110(Q1-Q3 59-198)pg/mL,脓毒性休克患者更高。
- 第1天bio-ADM与90天死亡率、多器官衰竭、血流动力学支持治疗(液体和血管加压药)平均强度及第一周血清乳酸变化轨迹相关。
- 入组时无休克患者中,bio-ADM预测新发心血管功能障碍(OR 1.9,95%CI 1.4-2.5,P<.0001,bio-ADM浓度每增加1个四分位距)。
- 第一周bio-ADM轨迹经临床相关协变量校正后预测90天死亡率(HR 1.3,95%CI 1.2-1.4,P<.0001)。
- 第7天bio-ADM降至110 pg/mL以下与90天死亡率明显降低相关;前7天bio-ADM变化不依赖于白蛋白治疗。
适用人群与场景
- 脓毒症或脓毒性休克患者,来自多中心ALBIOS试验,随机接受白蛋白或晶体液进行液体复苏。
研究设计与关键结果
- 研究类型为多中心ALBIOS试验的二次分析,纳入956例脓毒症或脓毒性休克患者,随机接受白蛋白或晶体液复苏。
- 第1天血浆bio-ADM中位数110(Q1-Q3 59-198)pg/mL,在脓毒性休克患者中更高,与90天死亡率、多器官衰竭、血流动力学支持治疗(液体和血管加压药)平均强度及第一周血清乳酸变化轨迹相关。
- 入组时无休克患者中,bio-ADM预测新发心血管功能障碍(OR 1.9,95%CI 1.4-2.5,P<.0001,bio-ADM浓度每增加1个四分位距)。
- 第一周bio-ADM轨迹经临床相关协变量校正后预测90天死亡率(HR 1.3,95%CI 1.2-1.4,P<.0001)。
- 第7天bio-ADM降至110 pg/mL以下与90天死亡率明显降低相关;前7天bio-ADM变化不依赖于白蛋白治疗。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(ALBIOS)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症患者中,循环生物活性形式的ADM可能有助于个体化血流动力学支持治疗,同时避免有害效应。
- 作者认为,bio-ADM可能的病理生理作用使其成为未来靶向治疗的潜在候选。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The biological role of adrenomedullin (ADM), a hormone involved in hemodynamic homeostasis, is controversial in sepsis because administration of either the peptide or an antibody against it may be beneficial.
METHODS: Plasma biologically active ADM (bio-ADM) was assessed on days 1, 2, and 7 after randomization of 956 patients with sepsis or septic shock to albumin or crystalloids for fluid resuscitation in the multicenter Albumin Italian Outcome Sepsis trial. We tested the association of bio-ADM and its time-dependent variation with fluid therapy, vasopressor administration, organ failures, and mortality.
RESULTS: Plasma bio-ADM on day 1 (median [Q1-Q3], 110 [59-198] pg/mL) was higher in patients with septic shock, associated with 90-day mortality, multiple organ failures and the average extent of hemodynamic support therapy (fluids and vasopressors), and serum lactate time course over the first week. Moreover, it predicted incident cardiovascular dysfunction in patients without shock at enrollment (OR [95% CI], 1.9 [1.4-2.5]; P < .0001, for an increase of 1 interquartile range of bio-ADM concentration). bio-ADM trajectory during the first week of treatment clearly predicted 90-day mortality after adjustment for clinically relevant covariates (hazard ratio [95% CI], 1.3 [1.2-1.4]; P < .0001), and its reduction below 110 pg/mL at day 7 was associated with a marked reduction in 90-day mortality. Changes over the first 7 days of bio-ADM concentrations were not dependent on albumin treatment.
CONCLUSIONS: In patients with sepsis, the circulating, biologically active form of ADM may help individualizing hemodynamic support therapy, while avoiding harmful effects. Its possible pathophysiologic role makes bio-ADM a potential candidate for future targeted therapies.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00707122.
参考来源
- Caironi P, Latini R, Struck J, et al. Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis. Chest. 2017. PMID: 28411114. doi:10.1016/j.chest.2017.03.035
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。